Arcus Biosciences, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Arcus Biosciences, Inc. (RCUS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of -1.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-02-25
- Arcus Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was -1.40%.
- Arcus Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was -0.50%.
- Arcus Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2025-12-31 | -1.40% 10-K · filed 2026-02-25 |
| 2024-12-31 | -0.50% 10-K · filed 2026-02-25 |
| 2023-12-31 | 0.00% 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |